CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats

被引:104
作者
Million, M
Wang, L
Wang, Y
Adelson, DW
Yuan, PQ
Maillot, C
Coutinho, SV
Mcroberts, JA
Bayati, A
Mattsson, H
Wu, V
Wei, JY
Rivier, J
Vale, W
Mayer, EA
Taché, Y
机构
[1] Univ Calif Los Angeles, CURE, Digest Dis Res Ctr,Div Digest Dis, VA Greater Los Angeles Healthcare Syst,Dept Med, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis, VA Greater Los Angeles Healthcare Syst,Dept Med, Los Angeles, CA USA
[3] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA
[4] AstraZeneca R&D, Molndal, Sweden
关键词
D O I
10.1136/gut.2004.051391
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Activation of corticotropin releasing factor 1 ( CRF1) receptors is involved in stress related responses and visceral pain, while activation of CRF2 receptors dampens the endocrine and some behavioural stress responses. We hypothesised that CRF2 receptor activation may influence visceral pain induced by colorectal distension ( CRD) in conscious rats, and assessed the possible sites and mechanisms of action. Methods: Male Sprague-Dawley rats were exposed to CRDs ( 60 mm Hg, 10 minutes twice, with a 10 minute rest interval). Visceromotor responses ( VMR) were measured by electromyography or visual observation. Spinal ( L6-S1) extracellular signal regulated kinase 1/2 ( ERK 1/2) activation following in vivo CRD and CRF2 receptor gene expression in the T13-S1 dorsal root ganglia ( DRG) and spinal cord were determined. Inferior splanchnic afferent ( ISA) activity to CRD ( 0.4 ml, 20 seconds) was assessed by electrophysiological recording in an in vitro ISA nerve-inferior mesenteric artery ( intra-arterial)-colorectal preparation. Results: In controls, VMR to the second CRD was mean 31 ( SEM 4)% higher than that of the first ( p < 0.05). The selective CRF2 agonist, human urocortin 2 ( hUcn 2, at 10 and 20 mu g/kg), injected intravenous after the first distension, prevented sensitisation and reduced the second response by 8 ( 1)% and 30 ( 5)% ( p, 0.05) compared with the first response, respectively. RT-PCR detected CRF2 receptor gene expression in the DRG and spinal cord. CRD ( 60 mm Hg for 10 minutes) induced phosphorylation of ERK 1/2 in neurones of lumbosacral laminae I and IIo and the response was dampened by intravenous hUcn 2. CRD, in vitro, induced robust ISA spike activity that was dose dependently blunted by hUcn 2 ( 1-3 mu g, intra-arterially). The CRF2 receptor antagonist, astressin(2)-B ( 200 mu g/kg subcutaneously or 20 mg intra-arterially) blocked the hUcn 2 inhibitory effects in vivo and in vitro. Conclusions: Peripheral injection of hUcn 2 blunts CRD induced visceral pain, colonic afferent, and spinal L6-S1 ERK 1/2 activity through CRF2 receptor activation in rats.
引用
收藏
页码:172 / 181
页数:10
相关论文
共 52 条
  • [21] POTENT, STRUCTURALLY CONSTRAINED AGONISTS AND COMPETITIVE ANTAGONISTS OF CORTICOTROPIN-RELEASING FACTOR
    GULYAS, J
    RIVIER, C
    PERRIN, M
    KOERBER, SC
    SUTTON, S
    CORRIGAN, A
    LAHRICHI, SL
    CRAIG, AG
    VALE, W
    RIVIER, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) : 10575 - 10579
  • [22] Evidence for visceral hypersensitivity in high-anxiety rats
    Gunter, WD
    Shepard, JD
    Foreman, RD
    Myers, DA
    Greenwood-Van Meerveld, B
    [J]. PHYSIOLOGY & BEHAVIOR, 2000, 69 (03) : 379 - 382
  • [23] International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands
    Hauger, RL
    Grigoriadis, DE
    Dallman, MF
    Plotsky, PM
    Vale, WW
    Dautzenberg, FM
    [J]. PHARMACOLOGICAL REVIEWS, 2003, 55 (01) : 21 - 26
  • [24] Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist
    Heinrichs, SC
    De Souza, EB
    Schulteis, G
    Lapsansky, JL
    Grigoriadis, DE
    [J]. NEUROPSYCHOPHARMACOLOGY, 2002, 27 (02) : 194 - 202
  • [25] ERK integrates PKA and PKC signaling in superficial dorsal horn neurons. II. Modulation of neuronal excitability
    Hu, HJ
    Gereau, RW
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 2003, 90 (03) : 1680 - 1688
  • [26] Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity
    Ji, RR
    Baba, H
    Brenner, GJ
    Woolf, CJ
    [J]. NATURE NEUROSCIENCE, 1999, 2 (12) : 1114 - 1119
  • [27] ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity
    Ji, RR
    Befort, K
    Brenner, GJ
    Woolf, CJ
    [J]. JOURNAL OF NEUROSCIENCE, 2002, 22 (02) : 478 - 485
  • [28] Differential interactions of urocortin/corticotropin-releasing hormone peptides with the blood-brain barrier
    Kastin, AJ
    Akerstrom, V
    [J]. NEUROENDOCRINOLOGY, 2002, 75 (06) : 367 - 374
  • [29] A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists
    Larsson, M
    Arvidsson, S
    Ekman, C
    Bayati, A
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2003, 15 (04) : 371 - 381
  • [30] Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans
    Lembo, T
    Plourde, V
    Shui, Z
    Fullerton, S
    Mertz, H
    Tache, Y
    Sytnik, B
    Munakata, J
    Mayer, E
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 1996, 8 (01) : 9 - 18